Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CLDX
SELLCelldex Therapeutics, Inc. · Healthcare · United States · $2.8B · Avg Vol: $44M/d
COMPANY DESCRIPTION
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic monoclonal antibodies for inflammatory, autoimmune, and oncology indications. The company's competitive moat is centered on its proprietary pipeline, particularly barzolvolimab, a clinical-stage candidate targeting mast cell-driven diseases like chronic urticaria. It operates as a high-potential biotechnology innovator with a robust intellectual property portfolio in immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.4M | 6.9M | 7.0M | 1.5M | -13.1% | 0.9M | 2.4M | — | 56.4% |
| EPS | -2.40 | -2.92 | -2.45 | -3.90 | — | -4.28 | -4.39 | -4.44 | — |
| Shares | 47.2M | 55.9M | 66.4M | 66.5M | +41.0% | 78.5M | — | — | — |
| Debt | 4.0M | 2.5M | 3.8M | 2.3M | -16.6% | 1.9M | — | — | — |
| Equity | 326.2M | 429.2M | 747.0M | 527.2M | 17.4% | — | — | — | — |
| Op CF | -103.7M | -107.3M | -157.8M | -210.9M | — | -222.2M | — | — | — |
| Inv CF | 89.9M | -105.8M | -290.1M | 209.1M | — | — | — | — | — |
| Fin CF | 4.1M | 218.5M | 441.4M | 2.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CLDX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc.(you) | $2.8B | 24 | SELL |
| IRON | Disc Medicine, Inc. | $2.8B | 23 | SELL |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.6B | 26 | SELL |
| KOD | Kodiak Sciences Inc. | $2.6B | 27 | SELL |
| NKTR | Nektar Therapeutics | $2.4B | 22 | SELL |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.6B | 28 | SELL |
| ALMS | Alumis Inc. | $3.6B | 22 | SELL |
| RCUS | Arcus Biosciences, Inc. | $3.6B | 22 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 26 | SELL |
| ATAI | AtaiBeckley Inc. | $2.7B | 31 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%